Aurora Cannabis Acquires Reliva LLC
May 28, 2020
Aurora Cannabis Inc. completed the acquisition of Reliva, LLC, a leading U.S. hemp-derived CBD consumer brand, in a transaction valued at approximately US$40 million in Aurora common shares plus an earn-out of up to US$45 million. The deal gives Aurora immediate U.S. retail CBD scale and distribution (Reliva products are sold in over 20,000 stores) and aims to combine Aurora's product innovation and international footprint with Reliva's U.S. retail relationships to accelerate growth.
- Buyers
- Aurora Cannabis Inc.
- Targets
- Reliva, LLC
- Sellers
- Members of Reliva
- Industry
- Consumer Products
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Ayr Wellness Acquires Cultivauna, LLC (Levia)
August 16, 2021
Food & Beverage
Ayr Wellness Inc. has entered into a binding letter of intent to acquire 100% of Cultivauna, LLC, the owner of the Levia brand of cannabis-infused seltzers and tinctures. The deal includes $20 million in upfront consideration (up to $10 million cash, remainder in stock) and an earn-out of up to $40 million in shares tied to 2022–2023 revenue targets; the acquisition is expected to close by the end of 2021 subject to regulatory approvals.
-
Aurora Cannabis Acquires Remaining Stake in MedReleaf Australia (Indica Industries)
February 8, 2024
Healthcare Services
Aurora Cannabis, through a wholly owned subsidiary, acquired the remaining ~90% equity interest in Indica Industries Pty Ltd (doing business as MedReleaf Australia) at an enterprise value of AUD$50 million. Consideration included AUD$9.45 million in cash and approximately 69.5 million Aurora common shares; MedReleaf Australia generated roughly AUD$40 million of trailing 12-month net revenue and holds the #2 position in the Australian medical cannabis market.
-
Tilray Acquires Aphria to Create New Tilray (Business Combination)
May 3, 2021
Consumer Products
Tilray and Aphria completed their previously announced business combination, with Aphria shareholders receiving 0.8381 Tilray shares for each Aphria common share. The combined company will operate as Tilray, creating a global cannabis consumer packaged goods leader with expanded geographic footprint, product portfolio and targeted annual pre-tax cost synergies of approximately US$81 million.
-
Elixinol Acquires 25% Stake in Pet Releaf
April 24, 2019
Consumer Products
Elixinol purchased a 25% equity stake in Altmeds LLC, the maker of the Pet Releaf hemp‑derived CBD pet product line, to strengthen supply arrangements and provide growth capital to scale the business. The investment will fund working capital, new product lines and expansion of a new 25,000 sq. ft. production facility; Elixinol’s president will join the Pet Releaf board.
-
Curaleaf Holdings Acquires Northern Green Canada
March 19, 2024
Pharmaceuticals
Curaleaf Holdings, Inc. has signed a deal to acquire Northern Green Canada, an EU-GMP certified Canadian licensed cannabis producer, to secure high-quality indoor EU-GMP flower supply and bolster Curaleaf's European and Australasian expansion. The acquisition is expected to close in Q2 2024 pending regulatory approvals and will strengthen Curaleaf's supply chain for key markets including Germany, Australia/New Zealand and the U.K.
-
Ayr Wellness Acquires Herbal Remedies Dispensaries, LLC
July 20, 2021
Retail
Ayr Wellness Inc. agreed to acquire 100% of Herbal Remedies Dispensaries, LLC, an operator of two licensed retail cannabis dispensaries in Quincy, Illinois, for total consideration of $30 million (comprised of $10 million in stock, $12 million in seller notes and $8 million in cash). The acquisition adds roughly 50 employees, expands Ayr into its eighth state (Illinois), is expected to close in Q4 2021 and is subject to customary regulatory approvals.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.